hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors

Chauhan, Aman; Prieur, Alexandre; Kolesar, Jill; Arnold, Susanne M.; Payen, Léa; Mahi, Younes; Vire, Bérengère; Sands, Madison; Evers, B. Mark; Joubert, Dominique; Anthony, Lowell

doi:10.3390/cancers14040863

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At time of this publication there is an ongoing prospective multi-center trial investigating human circulating progastrin (hPG80) as a biomarker for the monitoring of NENs (NTC04750954). hPG80 has been demonstrated to be elevated in the plasma of patients with a variety of low- and high-grade NENs when compared to healthy controls [ 67 ]. However, its wide-spread use is pending validation.…”

Section: Diagnosismentioning

confidence: 99%

Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability

Castle

Levy

Chauhan

2022

Cancers

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) encompass a variety of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) which can arise anywhere in the body. While relatively rare in the pediatric population, the incidence of NENs has increased in the past few decades. These neoplasms can be devastating if not diagnosed and treated early, however, symptoms are variable and can be indolent for many years. There is a reported median of 10 years from the appearance of the first symptoms to time of diagnosis. Considering some of these neoplasms have a mortality rate as high as 90%, it is crucial healthcare providers are aware of NENs and remain vigilant. With better provider education and easily accessible resources for information about these neoplasms, awareness can be improved leading to earlier disease recognition and diagnosis. This manuscript aims to provide an overview of both the most common NENs as well as the rarer NENs with high lethality in the pediatric population. This review provides up to date evidence and recommendations, encompassing recent changes in classification and advances in treatment modalities, including recently completed and ongoing clinical trials.

show abstract

Section: Diagnosismentioning

confidence: 99%

Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability

Castle

Levy

Chauhan

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…A novel blood-based biomarker that has shown promise in several different types of cancer is circulating progastrin or hPG 80 . It has been detected at significantly higher concentrations in the blood of cancer patients than in healthy blood donors [ 11 , 12 ]. In physiology, progastrin is the precursor of gastrin synthetized by antrum G cells and processed into gastrin [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort

Prieur¹,

Harper

Khan

et al. 2023

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background Recurrence and metastases are still frequent outcomes after initial tumour control in women diagnosed with breast cancer. Although therapies are selected based on tumour characteristics measured at baseline, prognostic biomarkers can identify those at risk of poor outcomes. Circulating progastrin or hPG80 was found to be associated with survival outcomes in renal and hepatocellular carcinomas and was a plausible prognostic biomarker for breast cancer. Methods Women with incident breast cancers from Calgary, Alberta, Canada enrolled in the Breast to Bone (B2B) study between 2010 to 2016 and provided blood samples prior to any treatment initiation. Plasma from these baseline samples were analysed for circulating progastrin or hPG80. Participant characteristics as well as tumour ones were evaluated for their association with hPG80 and survival outcomes (time to recurrence, recurrence – free survival, breast cancer specific survival and overall survival) in Cox proportional hazards regression models. Results The 464 participants with measurable hPG80 in this study had an average age of 57.03 years (standard deviation of 11.17 years) and were predominantly diagnosed with Stage I (52.2%) and Stage II (40.1%) disease. A total of 50 recurrences and 50 deaths were recorded as of June 2022. In Cox PH regression models adjusted for chemotherapy, radiation therapy, cancer stage and age at diagnosis, log hPG80 (pmol/L) significantly increased the risks for recurrence (Hazard Ratio (HR) = 1.330, 95% Confidence Interval (CI) = (0.995 – 1.777, p = 0.054)), recurrence-free survival (HR = 1.399, 95% CI = (1.106 – 1.770), p = 0.005) and overall survival (HR = 1.385, 95% CI = (1.046 – 1.834), = 0.023) but not for breast cancer specific survival (HR = 1.015, 95% CI = (0.684 – 1.505), p = 0.942). Conclusions hPG80 levels measured at diagnosis were significantly associated with the risk of recurrence or death from any cause in women with breast cancer. Since the recurrence rates of breast cancer are still relatively high amongst women diagnosed at an early stage, identifying women at high risk of recurrence at their time of diagnosis is important. hPG80 is a promising new prognostic biomarker that could improve the identification of women at higher risk of poor outcomes.

show abstract

The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective

Mariën,

Islam,

Chhajlani

et al. 2023

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors

Cited by 4 publications

References 27 publications

Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability

Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort

The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective

Contact Info

Product

Resources

About